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OBJECTIVE—This study examines the extent to which the
contractile deﬁcit of diabetic cardiomyopathy is due to altered
Ca
2 homeostasis.
RESEARCH DESIGN AND METHODS—Measurements of iso-
metric force and intracellular calcium ([Ca
2]i, using fura-2/AM)
were made in left ventricular (LV) trabeculae from rats with
streptozotocin-induced diabetes and age-matched siblings.
RESULTS—At 1.5 mmol/l [Ca
2]o, 37°C, and 5-Hz stimulation
frequency, peak stress was depressed in diabetic rats (10  1 vs.
17  2 mN/mm
2 in controls; P  0.05) with a slower time to peak
stress (77  3 vs. 67  2 ms; P  0.01) and time to 90% relaxation
(76  7 vs. 56  3 ms; P  0.05). No difference was found
between groups for either resting or peak Ca
2, but the Ca
2
transient was slower in time to peak (39  2 vs. 34  1 ms) and
decay (time constant, 61  3 vs. 49  3 ms). Diabetic rats had a
longer LV action potential (APD50,9 8 5 vs. 62  5 ms; P 
0.0001). Western blotting showed that diabetic rats had a reduced
expression of sarco(endo)plasmic reticulum Ca
2-ATPase
(SERCA)2a, with no difference in expression of the Na
/Ca
2
exchanger. Immunohistochemistry of LV free wall showed that
type I collagen was increased in diabetic rats (diabetic 7.1 
0.1%, control 12.7  0.1%; P  0.01), and F-actin content reduced
(diabetic 56.9  0.6%; control 61.7  0.4%; P  0.0001) with a
disrupted structure.
CONCLUSIONS—We ﬁnd no evidence to support the idea that
altered Ca
2 homeostasis underlies the contractile deﬁcit of
diabetic cardiomyopathy. The slower action potential and re-
duced SERCA2a expression can explain the slower Ca
2 tran-
sient kinetics in diabetic rats but not the contractile deﬁcit.
Instead, we suggest that the observed LV remodeling may play a
crucial role. Diabetes 57:2158–2166, 2008
D
iabetic cardiomyopathy was ﬁrst recognized by
Rubler et al. (1) in diabetic patients with con-
gestive heart failure but no evidence of coro-
nary atherosclerosis. Prominent defects of
diabetic cardiomyopathy include the prolonged duration
of contraction and relaxation (Boudina and Abel [2]) and
reduced cardiac compliance. The rat with streptozotocin
(STZ)-induced type 1 diabetes has been widely used as a
model of diabetic myopathy (3). STZ rats manifest a
variety of signs of myopathy, including cardiac rhythm
disturbances, prolonged contraction and/or slowed relax-
ation, and decreased contraction strength (4–6). Defects
in intracellular Ca
2 ([Ca
2]i) homeostasis have been impli-
cated in the impaired mechanical performance of the
diabetic heart (7,8). However, there is no consensus in
results from studies of intracellular Ca
2 homeostasis
performed on isolated cardiomyocytes; resting Ca
2 has
been shown to be decreased (9–11), increased (12,13), or
unchanged (14,15). Similarly, the amplitude of the Ca
2
transient is reported as decreased (11,16–18), increased
(12), or unchanged (19,20). It is possible that this lack of
consensus is due to different degrees of disease (diabetic
stage) and/or experimental conditions (e.g., different stim-
ulation frequencies and temperatures).
The purpose of this study was to reexamine the extent
to which changes in Ca
2 homeostasis underlie diabetic
cardiomyopathy. To do this, we used left ventricular (LV)
tissue at 37°C and stimulation frequencies of 0.1–7 Hz. The
latter encompasses rates used in other studies and the
normal heart rate for rats in the absence of -adrenergic
stimulation (21). Because LV remodeling is also known to
occur in diabetic cardiomyopathy (22,23), we examined
extracellular matrix type I and III collagen (the most
abundant collagen types in heart tissue [24]) and the thin
contractile ﬁlament F-actin by immunohistochemistry and
confocal microscopy and quantiﬁed their distribution and
abundance.
RESEARCH DESIGN AND METHODS
All animal use was approved by the University of Auckland animal ethics
committee. Chemical reagents were obtained from Sigma unless otherwise
stated.
Induction of STZ-induced diabetes. Diabetes was induced by a single
injection of STZ (60 mg/kg dissolved in 0.9% saline administered intrave-
nously) in adult male Wistar rats (200–250 g). Control rats received injections
of 0.9% saline alone. Blood glucose concentrations were measured 48 h after
STZ injection (Advantage II; Roche) and weekly thereafter. Diabetes was
diagnosed by a sustained glucose concentration 11 mmol/l. Insulin was not
administered, and all animals had free access to food and water.
Physiological measurements. Blood pressure measurements were carried
out on conscious animals using a tail-cuff method (MC4000 BP; Hatteras
Instruments, Cary, NC) after ﬁrst habituating animals to the procedure. Eight
weeks post-injection, animals were anesthetized (5% halothane initially,
maintained at 2% concentration in O2) and the electrocardiogram (ECG)
recorded (PowerLab data acquisition system; ADInstruments, Bella Vista,
Australia). QT interval was measured from the beginning of the QRS complex
to the end of the T wave, averaged over 6–10 cardiac cycles, and normalized
to the square root of RR interval (25).
The day after ECG measurements, the animals were again anesthetized, the
hearts removed and immersed in 4°C Krebs-Henseleit buffer (KHB) contain-
ing, in millimoles per liter: NaCl (118), KCl (4.75), KH2PO4 (1.18), MgSO4
(1.18), NaHCO3 (24.8), and D-glucose (10) with 2,3-butanedione monoxime (5)
and CaCl2 (0.5). Hearts were subsequently perfused at room temperature
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2158 DIABETES, VOL. 57, AUGUST 2008(KHB, gassed with 95% O2 and 5% CO2). Spontaneous action potentials were
recorded from LV free wall using glass microelectrodes (tip resistance 4–7
M ﬁlled with 3 mol/l KCl) and a Neuroprobe ampliﬁer (Model 1600; A-M
Systems, Carlsborg, WA) digitized at 10 kHz and acquired using a PowerLab.
Action potential duration (APD) was analyzed using IDL software (IDL
research Systems, Boulder, CO). APD50 and APD90 were measured as the time
taken for 50 and 90% repolarization of the action potential, respectively. A
small correction for varying heart rate was carried out using the square root
of the corresponding RR interval, by means similar to those used for the
measurement of the QT interval described above.
Isolation of LV trabeculae. An unbranched cylindrical trabecula was
dissected from the left ventricle while the heart was perfused with oxygenated
KHB containing 20 mmol/l l 2,3-butanedione monoxime and 0.25 mmol/l CaCl2.
The trabecula was then transferred to a Perspex bath on the stage of an
inverted microscope (Nikon Diaphot 300; Nikon, Tokyo, Japan) and continu-
ously superfused with oxygenated KHB. One end of the preparation was
mounted in a hook extending from a force transducer (AE801; SensorOne,
Sausalito, CA), with the other end held in a ﬁne snare protruding from a
stainless-steel tube. Following a 30-min stabilization period, the trabecula was
ﬁeld stimulated at 0.1 Hz with 5 ms square-wave pulses (20% above threshold)
delivered by a Digitimer D100 (Digitimer, Welwyn Garden City, Hertfordshire,
U.K.) and extracellular Ca
2 ([Ca
2]o) gradually increased to 1.0 mmol/l.
Isometric force was normalized to the trabecula cross-sectional area and
expressed as stress. LV trabeculae were not different in either length (diabetic
1.4  0.3 mm, n  9; control 1.5  0.2 mm, n  9) or cross-sectional area
(diabetic 0.023  0.008 mm
2, n  9; control 0.017  0.003 mm
2, n  9)
between groups.
Trabeculae were loaded with the ﬂuorescent Ca
2 indicator fura-2/AM (20
mol/l) at room temperature for 2 h. On completion of loading, the indicator
was washed out and sarcomere length adjusted to 2.1–2.2 m. Trabeculae
were illuminated at 340-, 360-, and 380-nm excitation wavelengths using a
spectrophotometric system (Cairn, Faversham, U.K.) and the ratio of the
emitted ﬂuorescence with 340- and 380-nm excitation was used as a measure-
ment of [Ca
2]i.
Data were acquired using LabView software (National Instruments, Austin,
TX) and analyzed ofﬂine. Unbiased measurement of Ca
2 transient and force
was made from data averaged over 7–10 cardiac cycles, using a custom
analysis program written in IDL. A ﬁve-parameter function was used to deﬁne
the properties of the averaged Ca
2 transient, as previously described (21).
Western blotting. Frozen LV tissue was homogenized in ice-cold lysis buffer
(50 mmol/l Tris-HCl, pH 8; 150 mmol/l NaCl; 1% NP-40; 0.5% sodium deoxy-
cholate; and 0.1% sodium dodecylsulphate) with a proteinase inhibitor cock-
tail (Roche, Indianapolis, IN) and then centrifuged at 13,000g f o r1ha t4°C.
Protein concentration in the supernatant was determined with a bicinchoninic
acid protein assay (Pierce, Rockford, IL). A total of 20 g protein was used for
Western blots using rabbit anti-NCX antibody (Ab) (1:500; Swiss Antibodies,
Swant, Switzerland) and mouse anti–sarco(endo)plasmic reticulum Ca
2-ase
(SERCA)2a Ab (1:1,000; Afﬁnity BioReagents, Golden, CO). Speciﬁc binding
was detected with a donkey anti-rabbit or anti-mouse IgG–horseradish
peroxidase conjugate (GE Healthcare, Buckinghamshire, U.K.) and ECL Plus
Western blotting detection reagents (GE Healthcare) according to the manu-
facturer’s instructions. An LA 3,000 image reader (Fuji Photo Film, Tokyo,
Japan) was used to detect signals and take images of the membranes. Images
were analyzed using Multi Gauge software (Fuji Photo Film).
Immunohistochemistry. Tissue for immunohistochemistry, frozen at 	80°C,
was sectioned at 30 m. The sections were dried (1 h), ﬁxed (ice-cold acetone,
10 min), and rehydrated (PBS, 5 min). Sections were then blocked (60 min,
10% goat serum in PBS) and immunolabeled (4°C) with rabbit anti-rat type I
and type III collagen Ab (1:100 in 5% goat serum/1% BSA/PBS; Chemicon,
Boronia, Australia). After washing (PBS), slides were stained for 2 h with
secondary Abs (1:200) (Alexa Fluor 488 goat anti-rabbit Ab; Invitrogen) and
phalloidin-rhodamine (1:50–100, Invitrogen) diluted in 5% goat serum/1%
BSA/PBS at room temperature. Slides were washed (PBS), mounted (antifade;
Dako), and imaged with a confocal microscope (Zeiss LSM410). Three
transverse optical sections from the LV wall adjacent to the endocardium
were analyzed from each animal (n  7, per group). F-actin and collagen
(types I and III) were quantiﬁed using Image J (http://rsb.info.nih.gov/ij) and a
custom-written IDL program based on signal thresholding. Results (means 
SEM) were expressed as percentage of cross-sectional area. Differences
between means were analyzed using either ANOVA or Student’s t test, as
appropriate, and were considered signiﬁcant at P  0.05.
RESULTS
The general characteristics of diabetic rats compared with
their age-matched control counterparts are shown in Table
1. Diabetes was conﬁrmed by a signiﬁcant (approximately
sixfold) elevation in blood glucose, 3 days after STZ
injection, that was maintained. Eight weeks post-injection,
diabetic rats had decreased body weight, tibial length, and
heart weight, but their heart weight–to–body weight ratio
was increased. In contrast, heart weight normalized to
tibial length was not different between groups (Table 1).
Analysis of ECG and LV action potential duration.
Diabetic rats had a slower heart rate under anesthesia and
a prolonged QT interval both before and after normaliza-
tion for heart rate (diabetic 192  4 ms, n  18; control
177  4 ms, n  11; P  0.05). Consistent with the longer
QT interval, the LV action potential was also prolonged in
diabetic rats. These results are summarized in Table 1.
Measurements of intracellular Ca
2 and isometric
force. Intracellular [Ca
2]i (fura-2 340/380 ratio) and iso-
metric force were measured in LV trabeculae under exper-
imental conditions that mimicked those in vivo (1.5 mmol/l
[Ca
2]o, 37°C, and 5 Hz). Figure 1A shows ﬁve consecutive
cardiac cycles recorded from representative control (solid
lines) and diabetic (dotted lines) trabeculae, superim-
posed for comparison. Parameters describing these data
are summarized in Table 2. No difference was found in
peak or resting [Ca
2]i between groups, but the kinetics of
the Ca
2 transient were slower for diabetic rats (increased
time to peak [Ca
2]i and time constant of Ca
2 transient
decay; P  0.05). In comparison with their control coun-
terparts, diabetic rats had decreased peak and developed
stress with a slower time course (increased time to peak
stress and time to 90% relaxation of stress; P  0.05).
Figure 1B shows superimposed Ca
2 transients (i),
twitches (ii), and phase plots (iii), obtained by combining
averaged data from seven trabeculae per group. The
[Ca
2]i-stress relationship (Fig. 1Biii) shows a right-shifted
TABLE 1
General characteristics of control and diabetic rats
Control rats Diabetic rats
Body weight (g) 433  12 (23) 237  10 (25)§
Heart weight (g) 1.60  0.07 (24) 1.24  0.05 (24)‡
Tibial length (mm) 42.3  0.4 (13) 38.6  0.6 (16)§
Heart weight:body weight (
 10
3) 3.7  0.1 (23) 5.3  0.2 (21)§
Heart weight:tibial length (g/mm) 0.040  0.002 (13) 0.035  0.002 (13)
Blood glucose (mmol/l) 5.0  0.1 (24) 30.7  0.9 (24)§
Systolic blood pressure (mmHg) 112  3 (16) 121  5 (11)
Heart rate (min
	1) 376  11 (16) 295  5 (11)§
APD50 (ms) 62  5 (6) 98  5 (7)§
APD90 (ms) 136  10 (6) 195  9 (7)§
Data are means  SEM (n). ‡P  0.001 and §P  0.0001, Student’s t test.
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(diabetic 29  7m Nm m
	2/ratio unit, n  8; control 67 
17 mN mm
	2/ratio unit, n  8; P  0.05), suggesting that
myoﬁbrillar Ca
2 sensitivity was reduced.
Effect of [Ca
2]o on [Ca
2]i and stress. Increased
cytoplasmic Ca
2 can paradoxically reduce sarcoplasmic
reticulum (SR) Ca
2 content when it increases the proba-
bility and frequency of spontaneous Ca
2 release from the
SR during diastole (26,27). This is an important factor for
in vitro studies in the rat, as it has been reported that the
rat is highly dependent on SR Ca
2 stores for contraction
(28) and susceptible to spontaneous SR diastolic Ca
2
TABLE 2
Intracellular Ca
2 and mechanical stress (for 1.5 mmol/l Ca
2o, 5 Hz, 37°C)
Control rats Diabetic rats
Peak 340/380 ratio 1.1  0.1 (10) 1.2  0.2 (7)
Resting 340/380 ratio 0.41  0.05 (10) 0.45  0.1 (7)
Time to peak ﬂuorescence (ms) 34  1 (9) 39  2 (7)*
Time constant of ﬂuorescence decay (ms) 49  3 (9) 61  3 (7)†
Maximum rate of rise of 340/380 ratio (s
	1) 24  3 (9) 21  3 (7)
Peak stress (mN/mm
2) 17  2 (9) 10  1 (8)†
Resting stress (mN/mm
2) 5  1 (9) 4  1 (8)
Time to peak stress (ms) 67  2 (9) 77  3 (9)*
Time to 50% relaxation (ms) 32  1 (9) 42  4 (9)†
Time to 90% relaxation (ms) 56  3 (9) 76  7 (9)†
Maximum rate of rise of stress (mN/mm
2 per s) 350  60 (9) 180  20 (9)†
Data are means  SEM (n). *P  0.01 and †P  0.05, Student’s t test.
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FIG. 1. Data from diabetic (dotted lines) and control (solid lines) rats at 5 Hz, 37°C, and 1.5 mmol/l [Ca
2]o superimposed for comparison.
A: Representative traces of ﬂuorescence (340/380 ratio) and force. B: Average data from 7 trabeculae per group. Ca
2 transient (i), stress (ii),
and phase plane analysis of the relationship between ﬂuorescence and stress during twitch (iii). Arrows indicate the direction of time.
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might be altering Ca
2 release, trabeculae were exposed
to a range of extracellular Ca
2 concentrations from 0.5 to
5 mmol/l. There was no difference between groups for
either resting [Ca
2]i (Fig. 2A) or resting stress (Fig. 2B)a t
all [Ca
2]o. Although peak [Ca
2]i and peak stress in-
creased with increasing [Ca
2]o in both groups, peak
stress was reduced in diabetic animals at all [Ca
2]o (P 
0.05; Fig. 2A and B). In contrast, there was no difference in
peak [Ca
2] between groups, consistent with the lack of a
difference in resting [Ca
2]i.
Figure 2C examines the relationship between peak
[Ca
2]i and peak stress and clearly shows that, regardless
of the peak [Ca
2]i, diabetic rats had decreased respon-
siveness to [Ca
2]i. It is well known that the time course of
the Ca
2 transient affects force responses and that a
decrease in the duration of the transient decreases force.
Figure 2C shows that regardless of the peak [Ca
2]i
reached, diabetic trabeculae developed less stress,
whereas Fig. 2D shows that they also had a slower Ca
2
transient (which would be expected to increase force
production [29]). The reduced slope of the relationship
between peak [Ca
2]i and peak force (Fig. 2C) is consis-
tent with diabetic rats having a diminished myoﬁbrillar
Ca
2 sensitivity.
Effect of stimulation frequency on [Ca
2]i and stress.
In cardiac muscle, force is also modulated by stimulation
frequency, and as noted above, most in vitro investigations
have been carried out at low stimulation frequencies. We
examined the response of trabeculae to stimulation fre-
quencies in the range 0.1–7 Hz (Fig. 3). Trabeculae from
control rats (n  6) showed a biphasic response for
developed stress and Ca
2transient amplitude with in-
creasing stimulation frequency (Figs. 3A and 3B). There
were no differences in peak or resting [Ca
2]i between
diabetic and control rats, except at 7 Hz, where resting
[Ca
2]i was increased in diabetic animals (Fig. 3A). The
positive phase of the force-frequency response was dimin-
ished in diabetic rats (n  6; Fig. 3B) such that, despite the
increase in the Ca
2 transient with frequency, force did
not follow. Both diabetic and control rats showed frequen-
cy-dependent acceleration in the decay of the Ca
2 tran-
sient (Fig. 3C) and force relaxation (Fig. 3D), but these
parameters were always slower for diabetic rats (P 
0.05).
Taken together, these results show that the reduced
contractility of diabetic rat hearts cannot be explained on
the basis of an altered [Ca
2]i, although there were
changes in Ca
2 homeostasis that slowed the Ca
2
transient.
Western blotting. The rate of decline of the Ca
2 tran-
sient is dominated by the rate of Ca
2 uptake by the SR
and, to a lesser extent, sarcolemmal Ca
2 extrusion by the
Na
/Ca
2 exchanger (NCX), which contributes 
15% (30).
Figure 4 shows Western blots of SERCA2a and NCX
protein expression. Diabetic rats had lower levels of
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FIG. 2. The effect of [Ca
2]o on ﬂuorescence and stress at 0.1 Hz and 37°C. Solid bars and symbols show data from diabetic rats (n  6); open bars
and symbols are matched controls (n  6). A: Effect of [Ca
2]o on peak and resting ﬂuorescence. B: Effect of [Ca
2]o on resting, developed, and
peak stress. C: Relationship between peak ﬂuorescence and peak stress. Control rats: R
2  0.97, slope  33.9. Diabetic rats: R
2  0.94, slope 
14.49. D: Effect of [Ca
2]o on time constant (tau) of ﬂuorescence decay. Control rats: R
2  0.96, slope 0.086. Diabetic rats: R
2  0.94, slope
0.125; P < 0.05. Data are means  SEM. Linear regression analysis was made from mean values, and dotted lines show the 95% CIs.
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signiﬁcantly altered. This result suggests that the origin of
the slowed Ca
2 transient in diabetic hearts resides in a
decrease in the SR uptake capacity.
Immunohistochemistry of type I and type III collagen
and F-actin. Because cardiac remodeling may contribute
to diabetic cardiomyopathy (23,24), we examined the
extracellular collagen content and the organization of
sarcomeric thin ﬁlaments (F-actin). Figure 5 shows images
of typical antibody-labeling patterns for type I collagen
(green) and phalloidin-labeled F-actin (red) in diabetic and
control rats. Diabetic hearts showed increased type I
collagen per endocardial cross-sectional area (diabetic
7.1  0.1% of area, control 6.2  0.2% of area; P  0.01)
without signiﬁcant change in type III collagen (diabetic
6.5  0.1% of area, control: 6.2  0.1% of area). Diabetic
rats also showed a more disorganized F-actin structure
with decreased F-actin content (diabetic 56.9  0.6% of
area, control 61.7  0.4% of area; P  0.0001).
DISCUSSION
Diabetic cardiomyopathy or “diabetic heart muscle dis-
ease” starts as an asymptomatic slowing in relaxation
kinetics (diastolic dysfunction) (31). As the syndrome
progresses, systolic function also becomes compromised,
which increases morbidity and mortality (32). In the
present study, STZ-injected rats were used as a model of
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ated in relation to cellular [Ca
2]i homeostasis, electrical
activity, and remodeling of the left ventricle.
Diabetic rats had a decreased heart rate with depressed
SR Ca
2-uptake capacity and no detectable change in
NCX. Although the cause of the decreased SA node
discharge rate was not examined, our data suggest a
possible explanation. SA nodal cell action potential gener-
ation is promoted by spontaneous SR Ca
2 release, which
produces inward current by NCX (Maltsev et al. [33]). In
our model, a reduced ability of the SR to take up Ca
2
might delay the time taken for the SR to reach the level of
Ca
2 that promotes spontaneous release. This would
therefore reduce SA nodal cell discharge rate, as observed.
At 1.5 mmol/l [Ca
2]o, 37°C, and 5 Hz, which are close to
physiological conditions, trabeculae from diabetic rats
showed depressed contractility with prolonged time for
contraction and relaxation (Table 2). This result is consis-
tent with previous studies from our group using the
isolated working heart (34) and from other research
groups, albeit under different conditions (8,17,35). Altered
intracellular Ca
2 homeostasis has previously been sug-
gested as underlying diabetic cardiac dysfunction (Pierce
and Russell [7] and Cesario et al. [36]) although, as noted,
results are inconsistent. Although some of these discrep-
ancies might be attributable to the extent of disease
progression (diabetic stage) and experimental conditions,
few studies have examined [Ca
2]i and the control of
contractility under near-physiological temperatures and
rates of stimulation. This problem is illustrated in Fig. 3; at
1 and 2.5 Hz, there was no detectable difference in
developed stress between groups, despite contractility
being very much reduced at all other frequencies tested in
diabetic rats. In the present study, experiments were
performed from a base of 37°C and 5 Hz, and our data
showed that diabetic rats had an unchanged resting
[Ca
2]i level, maximum rate of rise in ﬂuorescence, and
Ca
2 transient amplitude, despite showing reduced con-
tractility. These results are consistent with some previous
studies (14,15) performed on isolated cardiomyocytes at
35–37°C and 1 Hz. In contrast, results from other studies
showed a reduced Ca
2 transient amplitude or peak
[Ca
2]i (11,16–18), but it should be noted that those
experiments were performed at low temperature (21–
25°C) and low stimulation frequencies (0.2–0.5 Hz).
Our results also showed that diabetic rats had prolonged
time to peak [Ca
2]i and prolonged time constant of Ca
2
transient decay (Table 2), consistent with some other
studies (6,11,14–16). Although the time to peak [Ca
2]i
was slower, the rate of rise of the Ca
2 transient was not
A
C D
B
FIG. 5. Representative confocal images of LV free wall immunolabelled for type 1 collagen (green) and F-actin (red). A and B: Cross-section from
endocardium (25 objective, zoom 3) from control (A) and diabetic (B) rats. C and D: Longitudinal sections (63 objective, zoom 3) from
control (C) and diabetic (D) rats. (Please see http://dx.doi.org/10.2337/db08-0140 for a high-quality digital representation of this ﬁgure.)
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the trigger for Ca
2 release (ICa) was not reduced, with the
delayed peak of the Ca
2 transient likely due to the
prolonged action potential duration. The reduction in the
level of expression of SERCA2a (
50%), as detected by
Western blots (Fig. 4), appears sufﬁcient to explain the
reduction (
20%) in the rate of decline of the Ca
2
transient. The slower kinetics of the Ca
2 transient would
contribute to the prolonged time course of cardiac con-
traction and relaxation in diabetic rats, but it is unclear
whether the reduced rate of the decay in the Ca
2 tran-
sient is sufﬁcient to explain the slowed mechanical relax-
ation. By comparing contractions between normal and
diabetic rats at different stimulation rates, we can select
contractions that have similar rates of Ca
2 transient
decline to isolate the effect on contraction. For example, at
5 Hz, the diabetic rat Ca
2 transient decreases slightly
faster than that of the control rat at 2.5 Hz (Fig. 3C).
However, the time to 90% mechanical relaxation of the
diabetic rat at 5 Hz (Table 2) is about 80 ms, whereas that
of the control rat takes about 60 ms at 2.5 Hz. Similarly, for
50% mechanical relaxation, the times were 39 ms and 32
ms (for diabetic rats at 5 Hz and control rats at 2.5 Hz,
respectively). From these comparisons, we suggest that
the mechanical relaxation is intrinsically slower in dia-
betic animals and exacerbated by the reduced rate of
decrease of [Ca
2]i. In support of this idea, we also
observed an increase in the time to peak stress in diabetic
rats over and above that expected from the delayed time to
peak [Ca
2]i.
The slower kinetics of the Ca
2 transient in diabetic rats
may also be affected by the prolonged APD (Table 1),
altered intracellular Ca
2 handling, or the combination of
both. It is well known that maintained depolarization
slows the return of [Ca
2]i to resting levels (37), an effect
that is partly due to inhibition of Ca
2 extrusion by NCX.
On the other hand, slowed SR Ca
2 uptake should lead to
prolonged depolarization due to inward current generation
by forward-mode NCX. The latter explanation seems likely
because we found decreased levels of SERCA2a expres-
sion in the diabetic rat. Decreased SERCA2a expression
should alter the balance of Ca
2 homeostasis in favor of
increased Ca
2 extrusion via NCX and might be expected
to reduce SR Ca
2 content. However, Ca
2 extrusion via
NCX during the decline of the Ca
2 transient will lead to
Na
 entry, which, during the diastolic period, will increase
resting [Ca
2]i and help restore SR Ca
2 levels. This is
consistent with our observation of a slightly increased
resting [Ca
2]i in diabetic rats (at least at 0.1 Hz and varied
[Ca
2]o), although detailed modeling will be required to
determine whether the change in SR Ca
2 uptake is by
itself sufﬁcient to explain all the effects on the APD and
resting [Ca
2]i.
Although we found almost no effects on peak Ca
2 in a
variety of conditions, the ﬁnding that there was a reduced
rate of SR Ca
2 uptake and SERCA2a expression was
surprising, since these changes might be expected to
decrease SR Ca
2 content (and therefore the amplitude of
the Ca
2 transient). Simple interpretation of changes in
Ca
2 transient kinetics is complicated by the interaction of
some Ca
2 transport mechanisms with changes in mem-
brane potential during the action potential. To separate
these two effects, a logarithmic analysis of the decline of
the Ca
2 transient is shown in Fig. 6. It is clear that there
is a delay before the decline of ﬂuorescence becomes
exponential. It is notable that this delay is longer in
diabetic rats and that the duration corresponds closely to
the time for 50% action potential repolarization. After the
delay, the rate of decline of the Ca
2 transient was slower
in diabetic rats, as described above. The slowed initial
phase of the decrease in the Ca
2 transient must be due to
either continued sarcolemmal Ca
2 inﬂux or a failure for
SR release to terminate (because dCai/dt  Jinﬂux 	 Jefﬂux).
The latter factor would also be expected to reduce SR
Ca
2 content, but because the amplitude of the Ca
2
transient was not reduced, increased sarcolemmal Ca
2
inﬂux during this period seems more likely. Because the
50% repolarization potential corresponds to a time when
Ca
2 inﬂux via L-type Ca
2 channels terminates (38), the
increased duration of the diabetic action potential would
be expected to increase Ca
2 inﬂux and may therefore
explain why the Ca
2 is not decreased, in spite of a
decreased SR uptake capacity.
Phospholamban is an endogenous inhibitor of SERCA
activity in cardiac muscle, especially at low [Ca
2]i, and
might contribute to the differences in the decay of the
transient between groups. However, the inhibitory effects
of phospholamban are calcium dependent; as [Ca
2]i is
increased, the effects are diminished. Figs. 2D and 3D
show the time constant of Ca
2 decay as a function of the
peak ﬂuorescence for both diabetic and control trabeculae
under experimental conditions that alter [Ca
2]i. Linear
regression analysis for both datasets (Figs. 2D and 3D)
showed that the slopes of the regression lines were either
steeper (Fig. 2D) or not different (Fig. 3D) for diabetic
hearts, suggesting that decreased phospholamban does
not explain the slower decay of [Ca
2]i in diabetic hearts.
Diabetic rats showed depressed cardiac contractility,
even when peak [Ca
2]i was matched by altering stimula-
tion rate (Fig. 3A and 3B), suggesting that altered [Ca
2]i
handling was not the primary cause of contractile dysfunc-
tion. Because depressed cardiac myoﬁbrillar ATPase ac-
tivity occurs in diabetic cardiomyopathy (39), it might
seem obvious to attribute the contractile dysfunction to
this effect. However, we also observed a 
8% reduction in
the fractional area of actin ﬁlament (F-actin) per unit
cross-section that will also contribute to a reduction in
active stress. The reduced F-actin labeling per cross-
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FIG. 6. Logarithmic plot of averaged 340/380 ratio from diabetic (n 
7) and control (n  7) rat trabeculae. Dotted lines ﬁtted to each curve
indicate the linear portion of the response. Note that the decay in
ﬂuorescence becomes linear at approximately the APD50 for each
group but is delayed in diabetic rats.
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protein synthesis, increased protein degradation (40), and
reduced -actin mRNA expression (41). More importantly,
F-actin no longer showed a highly organized sarcomeric
distribution in diabetic hearts (Fig. 5D). Activation of
cardiac muscle myoﬁlaments involves a series of complex
interactions between the troponin complex, tropomyosin,
and F-actin. The contractile deﬁcit might therefore arise,
in part, from an overall reduction in the number of
myosin-binding sites available for crossbridge formation.
Additionally, changes to the sarcomeric organization of
F-actin might also explain the reduced myoﬁlament Ca
2
sensitivity in diabetic trabeculae.
Diabetic cardiomyopathy is also associated with in-
creased stiffness in the left ventricle (42). Types I and III
collagen are the most abundant collagen types in the heart,
forming 85 and 11% of the total collagen content, respec-
tively (24). Our results show an increase (14%) in type I
collagen in diabetic rats but no change in type III. How-
ever, any diastolic dysfunction arising from increased
collagen would be compounded by the reduced rate of
decline of the Ca
2 transient and its effects on force
production.
In summary, under physiological conditions, we ﬁnd no
evidence to support the idea that altered myocardial Ca
2
handling underlies the decrease in contractile force in
diabetic cardiomyopathy. Although decreased SR Ca
2
uptake exists, it is offset by an increase in action-potential
duration, thereby ensuring that SR Ca
2 content is main-
tained. Instead, our data indicate that the contractile
function is compromised by reduced and disrupted F-actin
in conjunction with the increased type I collagen. In
addition, we found evidence for a decreased myoﬁlament
sensitivity and slowed relaxation independent of the
changes in the Ca
2 transient. Although the contribution
of the observed structural changes to the contractile
deﬁcit in the diabetic heart cannot be evaluated at this
time, such changes deserve careful consideration in future
studies.
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